alogliptin

Alogliptin (SYR-322)(SYR-322) is a potent, selective inhibitor of DPP-4 with IC50 of <10 nM, exhibits greater than 10, 000-fold selectivity over DPP-8 and DPP-9.

Alogliptin-13CD3 is the deuterium-labeled Alogliptin. Alogliptin (T6192) is a selective inhibitor of DPP-4.

Alogliptin Benzoate (SYR 322)(SYR 322), an effective and specific DPP-4 inhibitor (IC50<10 nM), exhibits greater than 10, 000-fold selectivity over DPP-8/9. Alogliptin may inhibit inflammatory responses by preventing the toll-like receptor 4 (TLR-4)-mediated formation of proinflammatory cytokines.

(S)-Alogliptin Benzoate Salt-13C-D3 is the 13C and deuterated compound of (S)-Alogliptin Benzoate Salt.

Alogliptin (Standard) is a reference standard for research and analysis in studies involving Alogliptin. Alogliptin (SYR-322)(SYR-322) is a potent, selective inhibitor of DPP-4 with IC50 of <10 nM, exhibits greater than 10, 000-fold selectivity over DPP-8 and DPP-9.

DPP-4-IN-2 (compound b2) is a structural analog of Alogliptin and a potent dipeptidyl peptidase 4 (DPP-4) inhibitor with an IC50 value of 79 nM [1], suitable for diabetes research.

DPP-4-IN-1 (compound d1) is a highly potent inhibitor of DPP-4 (dipeptidyl peptidase 4) with an IC50 of 49 nM, making it suitable for diabetes research [1]. Structurally similar to Alogliptin, it can be effectively utilized for studying diabetes-related mechanisms.